Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Xetra  >  Bayer AG    BAYN   DE000BAY0017

BAYER AG (BAYN)

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

Bayer AG : Expansion of germplasm-pool for wheat:

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/14/2011 | 11:30am CEST
Bayer CropScience acquires access to wheat germplasm from leading Romanian agricultural research institution
Monheim, October 14, 2011 – Bayer CropScience and the National Agricultural Research and Development Institute (NARDI) in Fundulea/Romania have signed a license agreement. With this agreement, Bayer gains access to winter wheat germplasm of NARDI, the leading Romanian agricultural research institution. Its germplasm pool is renowned world-wide for its winter hardiness, high tolerance against drought, broad disease resistance and good milling and baking quality. Financial details were not disclosed.
“Improving the productivity of wheat cropping will be critical to achieving global food security. Our customers have turned to us to find new ways to help them, we have listened and are building a world-class research platform for wheat genetics. Our agreement with NARDI is another key building block in this strategy“, said Hartmut van Lengerich, Head of Cereals and Fungicides at Bayer CropScience. “To speed up development of new varieties, we have already entered into collaborations with the best partners in wheat research and breeding, reaching from Australia to Israel, France and Ukraine to the United States – and now Romania.”
“Producing enough wheat to feed the world is an immense challenge and anyone willing to invest in the effort to meet this challenge is welcome”, said Marian Verzea, General Director of NARDI. “NARDI is proud that the wheat germplasm developed by its breeding program will be used to speed up genetic progress in breeding better wheat cultivars for other parts of the world, too.”
Key figures about wheat:
With about 25 percent of the global agricultural land under wheat cultivation, it is the largest cereal crop in terms of acreage and one of the world’s most important staple foods. Wheat is the second most-produced cereal crop after corn with more than 650 million tons produced every year. Wheat productivity is increasing at less than 1 percent annually, while the annual global demand is growing at approximately double that percentage. Main wheat producing regions are Australia, the Black Sea Region, China, the EU, India and North America.
About Bayer CropScience
Bayer is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer CropScience, a subgroup of Bayer AG with annual sales of EUR 6.830 billion (2010), is one of the world’s leading innovative crop science companies in the areas of crop protection, non-agricultural pest control, seeds and traits. The company offers an outstanding range of products and extensive service backup for modern, sustainable agriculture and for non-agricultural applications. Bayer CropScience has a global workforce of 20,700 and is represented in more than 120 countries. This and further news is available at: www.press.bayercropscience.com.
About NARDI
NARDI Fundulea is recognized as the main agricultural research unit in Romania, due to the results obtained in breeding and crop management research & development regarding cereals, industrial and forage crops. Results of wheat breeding have a special place in NARDI’s research portfolio. NARDI’s twenty nine common wheat cultivars released since 1957 have had the largest share of the Romanian wheat seed market for more than 30 years, while nine NARDI wheat cultivars have been released in other countries, such as Canada, Argentina, Hungary, Turkey. Further information is available at: www.incda-fundulea.ro
Find more information at www.bayercropscience.com.
Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on BAYER AG
03/22 NOT INTENDED FOR U.S. AND UK MEDIA - : -- Bayer to Showcase Data on Growing Onco..
03/10DJCorrection to PPG Makes $22 Billion Offer for AkzoNobel Story on Thursday
03/10DJAkzo Nobel Shuns $22 Billion Takeover Bid -- WSJ
03/01 Banks, builders boost European shares as Trump-trade back on
03/01 Bayer sells 11 percent of Covestro for 1.46 billion euros
03/01 Banks, basic resources lift European shares on Trump-trade
03/01DJCovestro Shares Nosedive After Bayer Reduces Stake
02/28 NOT FOR DISTRIBUTION IN THE UNITED S : -- Bayer to reduce holding in Covestro --..
02/23DJBAYER : Financing Plan Will Raise Equity First Then Bonds -- WSJ
02/23DJBAYER : CEO Still Upbeat on Deal -- WSJ
More news
Sector news : Pharmaceuticals - NEC
03/24 NOVO NORDISK A/S : EMA panel backs Novo Nordisk's haemophilia B drug
03/24 YouTube's bid to grab TV dollars imperiled by advertiser revolt
03/23DJPRESS RELEASE : FDA Grants Approval for -3-
03/23DJPRESS RELEASE : FDA Grants Approval for -2-
03/23DJPRESS RELEASE : FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immuno..
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
03/25 Will The Dow/DuPont Merger Close In Q2?
03/22 Serelaxin Setback Puts Focus On Entresto
03/21 UPCOMING EVENTS : Alder's Migraine Test, Paratek's Antibiotic
03/19 MONSANTO : Important To National Security? (Lawmakers Against Acquisition Say Ye..
03/17 BLOOMBERG : Bayer set to sell seed assets to satisfy Monsanto combo concerns
Advertisement
Financials (€)
Sales 2017 49 246 M
EBIT 2017 9 827 M
Net income 2017 5 481 M
Debt 2017 11 066 M
Yield 2017 2,66%
P/E ratio 2017 16,90
P/E ratio 2018 15,64
EV / Sales 2017 2,02x
EV / Sales 2018 1,95x
Capitalization 88 483 M
More Financials
Chart BAYER AG
Duration : Period :
Bayer AG Technical Analysis Chart | BAYN | DE000BAY0017 | 4-Traders
Full-screen chart
Technical analysis trends BAYER AG
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 112 €
Spread / Average Target 4,3%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Werner Baumann Chairman-Management Board
Werner Wenning Chairman-Supervisory Board
Johannes M. Dietsch Chief Financial Officer
Katharina Jansen Head-Science & Research
Hartmut Klusik Human Resources, Technology & Sustainability
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
BAYER AG7.94%95 518
JOHNSON & JOHNSON8.91%340 163
ROCHE HOLDING LTD.8.73%219 545
PFIZER INC.4.68%202 474
NOVARTIS AG-0.94%195 096
MERCK & CO., INC.7.32%173 465
More Results